WINT חוב כולל להון Windtree

This price chart shows that Windtree Therapeutics (WINT) maintains a total debt-to-equity ratio of 0.00. While the company develops cardiology treatments, it faces liquidity shortages and the potential failure of medical trials. Efficient drug distribution to hospitals ensures prompt patient care, while the humanitarian nature of the industry minimizes external political risks and ensures stable operations across Western jurisdictions.

Total debt-to-equity measures the proportion of borrowed funds relative to shareholders' equity, determining the degree of financial leverage and the stability of the balance sheet structure. By analyzing the debt-to-equity ratio dynamics, an investor can see how the high burn rate for cardiology tests at Windtree Therapeutics (WINT) impacts the debt load, which is critical for a biotech company with a vulnerable cash flow.